Epidemiology and Pathogenesis of AIDS-Related Lymphomas
July 1st 1998This review by Dr. Aboulafia presents aspects of the epidemiology of acquired immunodeficiency (AIDS)-related lymphomas and their pathogenesis. The author’s main focus is in the molecular area, and the summary of epidemiology is well known to those interested in this field.
Vogelstein Discusses Gatekeeper Genes, Caretaker Genes
June 1st 1998NEW ORLEANS--Mutations in two types of genes, gatekeepers and caretakers, help explain both the progression of cells from normal to cancerous and the mechanism of actions of effective antitumor drugs, Bert Vogelstein, MD, of Johns Hopkins University School of Medicine, said at the plenary session of the 89th annual meeting of the American Association for Cancer Research.
How People Respond to Gene Testing for Adult Onset Disorders
June 1st 1998BALTIMORE--Patients choose genetic testing to help them make important life decisions, but often the risks and benefits are more complicated and less clear-cut than those of traditional medical tests, psychologist Ann-Marie Codori, PhD, of Johns Hopkins University, said at a seminar on genetic testing and counseling for adult onset disorders.
Feds Upgrade ‘Healthfinder’ Website
June 1st 1998WASHINGTON--The government has upgraded its health information website, "healthfinder," adding two new sections: "Smart Choices," to tell people how to find reliable health information on the Internet, and "Just for You," to tailor information by age and ethnicity, with the aim of enabling consumers to seek information geared to children or aging parents, for example. The website can be reached at www.healthfinder.gov.
ONS Receives Educational Grants to Fund Conferences
June 1st 1998The Oncology Nursing Society (ONS) recently received grants from Genentech, Inc., to fund two educational projects. A $96,000 grant will fund the ONS National Conference on Cancer Nursing Research to be held in 1999, and a $30,930 grant
Antigen-Based Antitumor Vaccines Seem Most Promising
June 1st 1998NEW ORLEANS--The next decade will be a critical time for translating new cancer vaccine approaches into standard therapies, said Drew Pardoll, MD, PhD, of Johns Hopkins University School of Medicine. In a talk at the plenary session of the 89th annual meeting of the American Association for Cancer Research, Dr. Pardoll noted that antigen-based anticancer vaccines offer perhaps the most promising approach.
Key Organizations Offer No Consensus on Mammography
June 1st 1998SAN DIEGO--Women between the ages of 40 and 49 must still decide for themselves if undergoing a mammography is appropriate for them, according to a panel of experts at the American College of Physicians (ACP) Annual Session. The inability of key organizations to come to a decisive conclusion is the result of conflicting studies and the fact that "each organization espouses different rules of evidence," said Mary E. Costanza, MD, professor of medicine, University of Massachusetts Medical School.
Cancer Prevention Efforts Should Not Wait on Definitive Causation Studies, Says Wynder
June 1st 1998NEW ORLEANS--"We can reduce the incidence of a cancer with preventive interventions without understanding their mechanism of action," said Ernst L. Wynder, MD, DSc, Dr.med.h.c., president and medical director of the American Health Foundation in New York. Dr. Wynder gave the Seventh AACR American Cancer Society Award Lecture on Cancer Epidemiology and Prevention at the American Association for Cancer Research meeting.
‘The March’ Opens Broad-Based Campaign
June 1st 1998WASHINGTON--"The March . . . Coming Together to Conquer Cancer" rings of militancy. It has an American war hero, retired US Army General H. Norman Schwarzkopf, as its honorary chairman. Its monthly newsletter is subtitled "A Campaign Bulletin." And when leaders and supporters of The March held a press briefing to talk about the nationwide event scheduled for Sept. 26, the rhetoric matched.
The CARET and the Stick: How to Stop a Trial
June 1st 1998BETHESDA, Md--Ending a clinical trial of a promising intervention may be just as difficult and delicate as starting one. The stopping point, Gilbert S. Omenn, MD, PhD, said at the American Society of Preventive Oncology meeting, applies to both the desired effect (or efficacy) and adverse effects (toxicity).
Women’s Dissatisfaction With Body Image Can Affect Smoking
June 1st 1998Women smokers who overestimate their body size may be more likely to continue smoking, said researchers at The Miriam Hospital in Providence. Results of a study led by Teresa K. King, PhD, of the hospital’s Center for Behavioral and
Cigars Are Butt of NCI’s New Cancer Risk Report
June 1st 1998BETHESDA, Md--The National Cancer Institute has raised a red flag to the nation’s current "hot" smoking fad. It warns that daily cigar smoking can cause cancer of the lip, tongue, mouth, throat, larynx, esophagus, and lung. Cigar smoking is also responsible for chronic obstructive pulmonary disease and coronary heart disease.
Tobacco Could Be an Issue in the Next Elections
June 1st 1998WASHINGTON--President Clinton is becoming increasingly ensnared in the tobacco wars on Capitol Hill, where partisan politics and philosophical differences threaten passage of national tobacco legislation. If no bill is passed before the November elections, many believe the issue could become even more politicized.
Lawyer Tells Cancer Patients How to Fight Job Discrimination
June 1st 1998NEW YORK--People do not generally think about their civil rights when they get cancer, but they may need them at some point in the workplace, attorney L. Susan Scelzo Slavin, of Slavin Law Firm, Jericho, NY, said during a Cancer Care, Inc. teleconference for cancer survivors.
NCI Launches Two New Efforts to Recruit Patients Into Clinical Trials
June 1st 1998BETHESDA, Md--The National Cancer Institute has published a new brochure and opened a new website, both designed to encourage cancer patients to enroll in clinical trials. "Taking Part in Clinical Trials: What Cancer Patients Need to Know" provides an overview of cancer treatment trials and answers questions that patients might have about them. Novartis Pharmaceuticals provided partial funding for the pamphlet.
Incidence of AIDS-Related Cancers Falls With Use of HAART
June 1st 1998BETHESDA, Md--In theory, highly active antiretroviral therapies, or HAART, should reduce the incidence of AIDS-related Kaposi’s sarcoma (KS) and non-Hodgkin’s lymphomas (NHL) by improving the immune functioning of HIV-infected individuals. Theory appears to be working out, at least with regard to lowering the risk of KS, according to several papers presented at the NCI’s 2nd National AIDS Malignancy Conference.
Chemotherapy May Improve Quality of Life of Patients With Incurable Cancer
June 1st 1998Chemotherapy can improve the quality of life of people with incurable cancer if it is administered with the understanding that, although the disease will not be eradicated, the patient can be made to feel better, said an oncologist at Stanford University Medical Center.
Congress Posts 39,000 Tobacco Documents on the Internet
June 1st 1998WASHINGTON--The House of Representatives Commerce Committee has posted 39,000 tobacco company documents on its website to allow the public to review the papers and determine for itself whether the tobacco companies are guilty of fraud for hiding knowledge of the health ramifications of smoking.
Incorporating Platelet Growth Factors Into Guidelines
June 1st 1998FORT LAUDERDALE, Fla--Recently, the FDA approved recombinant interleukin-11 (rIL-11 or oprelvekin, Neumega) for the prevention of severe thrombocytopenia in cancer patients with solid tumors or lymphoma. The availability of platelet growth factors represents a significant breakthrough in oncology, and methods are needed to help incorporate these agents into clinical practice guidelines.
Oncology Pharmacists Urged to Increase Visibility to Patients
June 1st 1998WASHINGTON--Selma Schimmel, a 15-year cancer survivor, brought a message to an international audience that most of them probably never expected to hear from a radio talk-show host. She urged oncology pharmacists to launch an aggressive outreach program to let cancer patients know that pharmacists can and do answer patients’ questions about chemotherapy and its side effects.